KIM MK, BANEVICIUS MA, ZHONG M, NIGHTINGALE CH, NICOLAU DP; Interscience Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago, Ill.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2001 Dec 16-19; 41: abstract no. A-935.
Hartford Hospital, Hartford, CT
BACKGROUND: Quinupristin-dalfopristin (Q/D) is often utilized in critically ill patients, some of which require CVVH. This study was undertaken to determine the clearance of Q/D and their main active metabolites (RPR 100391, RP 69012, RP 12536) via CVVH in the swine model. METHODS: Q/D 7.5 mg/kg was intravenously administered over 0.5 h to 12 swine after the induction of acute renal failure by ligation of the renal arteries. At 0.5 h post injection, the CVVH procedure was initiated and continued for 8 hours at the following pump rates: (1) 100 mL/min, (2) 200 mL/min, and (3) 100 mL/min with dialysis (flow rate:1 L/h). Blood and ultrafiltrate samples were collected at 1 h intervals and assessed by a validated HPLC method. RESULTS: Plasma analysis suggests rapid metabolism to the main active metabolites which are considerably cleared as demonstrated by high clearance and sieving coefficient estimates (Table). CONCLUSION: These data reveal that Q/D are rapidly metabolized and the metabolites are cleared to a large extent via CVVH. Due to the considerable contribution of the metabolites to overall in vivo activities, additional studies are required to fully quantify their removal before final dosage modifications for patients undergoing CVVH can be recommended. [table: see text]
Publication Types:
Keywords:
- Animals
- Critical Illness
- Humans
- Kidney Failure, Acute
- Renal Dialysis
- Swine
- Virginiamycin
- quinupristin-dalfopristin
Other ID:
UI: 102269395
From Meeting Abstracts